Jane Morgan’s Post

𝘼𝙄 𝙋𝙧𝙚𝙙𝙞𝙘𝙩𝙞𝙫𝙚 𝘽𝙚𝙝𝙖𝙫𝙞𝙤𝙪𝙧 𝘼𝙣𝙖𝙡𝙮𝙨𝙞𝙨 𝙩𝙤 𝘼𝙨𝙨𝙚𝙨𝙨 𝘼𝙪𝙩𝙞𝙨𝙢 𝘾𝙖𝙣𝙫𝙖𝙨𝘿𝙭 𝙗𝙮 𝘾𝙤𝙜𝙣𝙤𝙖 (𝙝𝙩𝙩𝙥𝙨://𝙘𝙤𝙜𝙣𝙤𝙖.𝙘𝙤𝙢) is an innovative tool designed for the early diagnosis of Autism Spectrum Disorder (ASD) in children aged 1.5 to 6 years. It incorporates several advanced features for predictive behavior analysis aimed at assessing the risk of Autism Spectrum Disorder (ASD) in children. Here are more details about its working features: 𝙑𝙞𝙙𝙚𝙤 𝘼𝙣𝙖𝙡𝙮𝙨𝙞𝙨 𝙃𝙤𝙢𝙚 𝙑𝙞𝙙𝙚𝙤 𝙎𝙪𝙗𝙢𝙞𝙨𝙨𝙞𝙤𝙣: Caregivers can upload home videos of their children, which are analyzed using machine learning algorithms to identify behavioral markers associated with ASD. 𝘽𝙚𝙝𝙖𝙫𝙞𝙤𝙧𝙖𝙡 𝘿𝙖𝙩𝙖 𝙄𝙣𝙩𝙚𝙜𝙧𝙖𝙩𝙞𝙤𝙣: The tool combines video analysis with behavioral data collected through caregiver questionnaires, providing a comprehensive view of the child's behavior. 𝙍𝙞𝙨𝙠 𝘼𝙨𝙨𝙚𝙨𝙨𝙢𝙚𝙣𝙩 𝘼𝙪𝙩𝙤𝙢𝙖𝙩𝙚𝙙 𝙎𝙘𝙤𝙧𝙞𝙣𝙜 : CanvasDx generates a risk score based on the analysis, indicating the likelihood of ASD. This score helps clinicians make informed diagnostic decisions. 𝘾𝙡𝙞𝙣𝙞𝙘𝙖𝙡 𝙄𝙣𝙨𝙞𝙜𝙝𝙩𝙨 : The tool offers insights into specific behaviors that may be indicative of ASD, aiding in targeted discussions during clinical evaluations. 𝙐𝙨𝙚𝙧-𝙁𝙧𝙞𝙚𝙣𝙙𝙡𝙮 𝙄𝙣𝙩𝙚𝙧𝙛𝙖𝙘𝙚 𝙄𝙣𝙩𝙪𝙞𝙩𝙞𝙫𝙚 𝘿𝙖𝙨𝙝𝙗𝙤𝙖𝙧𝙙: The platform features an easy-to-navigate dashboard for caregivers and clinicians, facilitating seamless interaction with the tool's functionalities. 𝙁𝙚𝙚𝙙𝙗𝙖𝙘𝙠 𝙈𝙚𝙘𝙝𝙖𝙣𝙞𝙨𝙢: Caregivers receive feedback on the analysis, which can guide them in seeking further evaluation or intervention if necessary. These features collectively enhance the diagnostic process, making it more efficient and accessible for families. #AI #AutismDiagnosis #PredictiveBehaviorAnalysis #AutismAwareness #ASDAssessment #AutismScreening #EarlyIntervention #MachineLearning #VideoAnalysis #CaregiverSupport #CanvasDx #Cognoa #BehavioralData #ChildHealth #AutismRisk #ClinicalInsights #InnovativeHealthcare #HealthTech #AIinHealthcare #PediatricDiagnosis #AutismSpectrumDisorder

Metabolism and ASD may be linked, according to a new study from the University of California San Diego School of Medicine. Researchers have uncovered a new link between changes in metabolism that occur sometime between birth and the presentation of ASD sometime in childhood. When studying the metabolic profiles of children with and without ASD, researchers uncovered changes to certain pathways. The ones most affected were responsible for the cell danger response: a natural and universal cellular reaction to injury or metabolic stress. The body has biochemical safeguards in place that can shut down these reactions once the danger has passed; researchers hypothesized that autism occurs when these safeguards fail to develop normally. What does this mean for children with ASD? In the future, the identification of the pathways may help doctors identify children with ASD earlier, and, in turn, help them provide early intervention services that will improve their quality of life. Source: https://loom.ly/MHyplfw #EssentialSpeechandABATherapy #autistic #autisticrights #earlychildhood #autistickids #developmental #diagnosis #inclusivitymatters #parentsofautisticchildren #earlyintervention #autisticlife #AutismMom #AutismDad #AutismFamily #ThisIsAutism #EarlyChildhood #AutismSupport #SpecialNeeds #spd #Sensory #EarlyChildhoodEducation #Preschooler

An analysis undertaken by $NTI on Autism Spectrum Disorder (#ASD) patients participating in the Phase II/III NTI164 clinical trial has demonstrated further beneficial improvements, as measured by the clinician via the Clinical Global Impression - Severity of illness Scale (CGI-S): https://lnkd.in/gU4ZtEuH For patients receiving NTI164 (n=26) there was a 36% improvement from week 8 to week 12 and 56% improvement from baseline (Day 0) to week 12. Patients who initially received placebo (n=28) then received NTI164 after week 8 onwards and showed immediate positive clinical benefits (21% improvement) after just 4 weeks of treatment. #Neurotech #NTI #NTI164 #AutismResearch #ASX #ASXNews #ASDtherapy #NeurotechClinicalTrials #NeurologicalDisorders #ClinicalTrialResults Autism Speaks Aspect Autism Friendly #autism

🚨Smashing News! 📰

Longitudinal change in symptom severity in children with ASD: Results from the ELENA cohort https://lnkd.in/eFs9CRv2 N=575 kids (2-12 years) diagnosed with autism/ASD. Results based on gold-standard ADOS scores: "The ADOS CSS total score changed for half of the sample, reflecting an increase in ASD severity for 21.9% and a decrease for 29.1% of children." Not for everyone but nearly a third of the cohort were reported to show decreasing autism severity over a 3 year period. More to come from this initiative. Really do hope that someone, somewhere might be wondering whether there could be biological correlates related to these symptoms changes. But for now, it all adds to the pluralisation of autism - the autisms - on the basis of symptom trajectories.

🌍 Exciting developments in the autism spectrum disorder (ASD) diagnosis market! According to The Business Research Company’s latest report, this market has experienced significant growth, increasing from $25.54 billion in 2023 to $27.39 billion in 2024—a robust CAGR of 7.2%. 🚀 Key drivers include heightened ASD awareness, expanded diagnostic criteria, and advancements in diagnostic tools. With public health campaigns and improvements in healthcare infrastructure, we’re witnessing remarkable progress. Looking ahead, the market is projected to reach $36.35 billion by 2028, with an impressive CAGR of 7.3%. This growth is fueled by early screening programs, a focus on precision medicine, and groundbreaking research into biomarkers. Innovative technologies, AI-powered diagnostic platforms, and the expansion of specialized diagnostic centers are transforming the landscape, enabling earlier and more accurate diagnoses. Notably, Fletch Equity's recent acquisition of Autism Spectrum Interventions (ASI) marks a strategic move to further enhance ASD care. As the market continues to evolve, we can expect even greater strides in improving outcomes for individuals and families affected by autism. 🌟 https://lnkd.in/gwvnKvRB #AutismAwareness #HealthcareInnovation #MarketGrowth #ASDDiagnosis

🎯Clinical Trial Success🎯: Autism drug NTI164 Improves Quality of Life for Children 👏Improvements in Anxiety, Depression and Mood👏 Neurotech International Ltd's Executive Director Thomas Duthy released more data today on a drug that looks to be widely beneficial drug for #autism (and potentially other associated diseases #rettsyndrome, #PANS, #PANDAS). The Phase II/III autism spectrum disorder (#ASD) clinical trial of NTI164 showed significant positive results in reducing #anxiety, #depression, and #mood issues in children, assessed using the ADAM Scale. (time to start asking about the "adult version") Key points: ✔40-50% of autistic children have significant anxiety; 10-20% have depression. ✔Children on NTI164 showed clinical improvements even when on existing anxiety/depression meds. ✔ Significant improvement in ADAMS total score from day 0 to week 8 (p<0.001). ✔NTI164 led to significant improvements in depressed mood, social avoidance, general anxiety, and obsessive/compulsive behaviour. Positive results reinforce NTI164's potential as a chronic therapy for autism.

Registration is open for our next webinar! Speaker: Susanna Mierau Wednesday, September 11, 2024, 7-8.15pm ET 𝗧𝗼𝗽𝗶𝗰: 𝗔𝗰𝗰𝗲𝘀𝘀 𝗕𝗮𝗿𝗿𝗶𝗲𝗿𝘀 𝘁𝗼 𝗠𝗲𝗱𝗶𝗰𝗮𝗹 𝗖𝗮𝗿𝗲 - 𝗪𝗼𝘂𝗹𝗱 𝘆𝗼𝘂 𝘁𝗿𝗲𝗮𝘁 𝗮 𝗯𝗿𝗼𝗸𝗲𝗻 𝘁𝗼𝗼𝘁𝗵 𝘄𝗶𝘁𝗵 𝗔𝗯𝗶𝗹𝗶𝗳𝘆? Live Q&A included. All NCSA webinars are free. Pre-registration is required. The talk focuses on the challenges limited verbal or non-verbal adults with autism spectrum disorder (ASD) face getting access to medical care and strategies for addressing these needs in our community. A recent study of over 1500 adults with ASD in the Kaiser medical system revealed that nearly all medical conditions are more common in people with ASD than age- and sex-matched controls (Croen et al., 2015). Yet limited verbal or nonspeaking adults with ASD can have difficulty getting the standard of care even for common conditions in adult medical facilities. Dr. Mierau will discuss these challenges and strategies for providing adult services to this highly vulnerable patient population. This talk will focus on using a neurology lens to understand more about the brain areas that can be affected in autism spectrum disorder (ASD) and how this alters communication styles. Following this session, participants will be able to: --identify challenges adults with ASD and limited communication skills face in getting medical care. --discuss behavior as a form of communication in limited verbal or nonspeaking adults with ASD and the role altered sensory perception may play in behavior. --discuss strategies for improving access and quality of medical care for limited verbal or nonspeaking adults with ASD in our communities. Please register here: https://lnkd.in/g7u7d5Z8 #autism #severeautism #profoundautism #neurology #healthequity #healthcareaccess

Families with Autistic kids aren't getting the help they need. Finding help shouldn't be a full time job. It shouldn't take a year to get an Autism diagnosis and then another 9 months to get into therapy. The current system expects families under tremendous stress, with kiddos who are really struggling and need support right now, to jump through so many hoops, only to wait and wait, and then hit more barriers. And when parents finally get their child into therapy, they often aren't happy with the results. The typical therapy recommended for Autistic children is Applied Behavior Analysis (ABA). In addition to the potential risks associated with ABA, the time and cost can be prohibitive for many families. (https://lnkd.in/eRC8Q5Ec; https://lnkd.in/e2hDaCDz; https://lnkd.in/eXXAXA5K) Many families with Autistic children find themselves in a place of giving up hope of getting help for their child and feel that they just have to manage challenges all on their own. And this is just not ok. Kids shouldn't have to wait years when getting help quickly is paramount to their healthy development and future success. My goal is to help families improve their Autistic child's sleep, learning, behavior and social skills using evidence based, neurodivergent-affirming holistic approaches that empower kids with self-care and self-advocacy skills that will serve them throughout their lives. No one should have to figure it all out on their own. If you'd like to learn more about my approach to helping Autistic kids thrive, I welcome you to subscribe to my emails here: https://lnkd.in/eHCWpWx3 #Neurodivergentaffirming #Autistickids #Neurodivergentkids #Autismresources #ABA